

Oxtellar XR[®] (oxcarbazepine) – First-time generic

- On September 1, 2024, <u>Apotex launched</u> an <u>AB-rated</u> generic version of Supernus' <u>Oxtellar XR</u> (oxcarbazepine) extended-release tablets.
- Oxtellar XR is approved for the treatment of partial-onset seizures in patients 6 years of age and older.
- Oxcarbazepine is also available generically as a suspension and a tablet.
 - The oral suspension and tablet are approved for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.